For what it's worth, Morgan Stanley thinks Tysabri will return to market, but its commercial impact "may be limited." Can someone explain why Morgan Stanley knows more about the drug's future than you or me?
Link
technorati tag: multiple sclerosis
Subscribe to:
Post Comments (Atom)
1 comment:
Doug, Morgan Stanley probably knows more about Tysabri's future than patients and doctors because brokers have been paying off researchers for advance info!
Recently read an article about that -- pharm researchers being bribed by brokers for possible advance info about this drug or that drug. they didn't mention Tysabri or any other M.S. treatment specifically, but when I read it, i immediately thought 'AHA -- so that's why we see all this news in the financial section before it hits the medical section!'
Post a Comment